Greenwich Lifesciences | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.3, beating the estimate of USD -0.36.

EBIT: As of FY2025 Q3, the actual value is USD -4.197 M.

Segment Revenue

• Greenwich LifeSciences, Inc. did not generate any revenue for the three and nine months ended September 30, 2025 and 2024.

Operational Metrics

• Net Loss: The company reported a net loss of - $4,151,845 for the three months ended September 30, 2025, compared to - $2,668,713 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $11,435,485, compared to - $7,748,590 in 2024.
• Research and Development Expenses: Increased by 54% to $3,521,576 for the three months ended September 30, 2025, and by 42% to $9,630,604 for the nine months ended September 30, 2025.
• General and Administrative Expenses: Increased by 49% to $653,066 for the three months ended September 30, 2025, and by 65% to $1,872,323 for the nine months ended September 30, 2025.

Cash Flow

• Net Cash Used in Operating Activities: - $6,738,796 for the nine months ended September 30, 2025, compared to - $5,414,337 for the same period in 2024.
• Net Cash Provided by Financing Activities: $6,453,784 for the nine months ended September 30, 2025, compared to $4,247,280 in 2024.

Unique Metrics

• Stock-based Compensation: The company expensed $4,632,642 in stock-based compensation for the nine months ended September 30, 2025, compared to $1,783,566 in 2024.

Future Outlook and Strategy

• Core Business Focus: Greenwich LifeSciences, Inc. is focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company plans to expand Flamingo-01 into Europe with up to 150 sites globally.
• Non-Core Business: The company does not currently generate revenues or profit, and the Chief Operating Decision Maker evaluates performance through analysis of segment expense information.